A new publication concerning retatrutide and related compounds appeared on August 21, 2026. The paper, titled "GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation," was published in Current Psychiatry Reports.
The publication is described as a systematic evaluation using a Bradford Hill informed approach. It addresses psychopharmacology and putative neuropsychiatric associated effects linked to GLP-1 and dual GIP/GLP-1 receptor agonists, a drug class that includes retatrutide.
No specific findings, conclusions, or results from the paper have been provided in this report. This brief reflects only the existence and bibliographic details of the publication as listed in the source record. Readers should consult the original article for its methodology and conclusions.
This item is intended to inform readers that this publication now exists in the scientific literature, not to characterize its content or implications. For more background on retatrutide, including its regulatory status and general information, readers can consult the compound overview.